“`html
Berenberg Bank reiterated coverage of Hikma Pharmaceuticals (OTCPK:HKMPF) with a Buy recommendation on November 6, 2025. The average one-year price target for the company is set at $33.13/share, representing a potential upside of 31.21% from its recent closing price of $25.25/share. Price targets range from a low of $26.54 to a high of $39.88.
Projected annual revenue for Hikma Pharmaceuticals is $2.88 billion, a 10.45% decrease. Institutional ownership has increased by 38.93% in the last three months, totaling 8.51 million shares, despite a decrease in the number of institutions holding positions by 2.44% to 40.
“`
